Expression of Yes-associated protein (YAP) in metastatic breast cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 9, 2015, Pages 11248-11257

  Kim, Hye Min ^a   Jung, Woo Hee ^a   Koo, Ja Seung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Breast cancer; Metastasis; YAP

Indexed keywords

PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL NUCLEUS; CHEMISTRY; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHOSPHORYLATION; RISK FACTOR; SECONDARY; TIME FACTOR; TISSUE MICROARRAY; TREATMENT OUTCOME; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BIOMARKERS, TUMOR; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL NUCLEUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; PHOSPHOPROTEINS; PHOSPHORYLATION; RISK FACTORS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; UP-REGULATION;

EID: 85013042296     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Zhao B, Tumaneng K and Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 2011; 13: 877-883.
2. Basu S, Totty NF, Irwin MS, Sudol M and Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003; 11: 11-23.
3. Tufail R, Jorda M, Zhao W, Reis I and Nawaz Z. Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas. Breast Cancer Res Treat 2012; 131: 743-750.
4. Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, Gangeswaran R, Manson-Bishop C, Smith P, Danovi SA, Pardo O, Crook T, Mein CA, Lemoine NR, Jones LJ and Basu S. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 2008; 15: 1752-1759.
5. Zhi X, Zhao D, Zhou Z, Liu R and Chen C. YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor. Am J Pathol 2012; 180: 2452-2461.
6. Wang X, Su L and Ou Q. Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. Eur J Cancer 2012; 48: 1227-1234.
7. Weil RJ, Palmieri DC, Bronder JL, Stark AM and Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol 2005; 167: 913-920.
8. Woodhouse EC, Chuaqui RF and Liotta LA. General mechanisms of metastasis. Cancer 1997; 80: 1529-1537.
9. Abali H and Celik I. High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel. Am J Clin Oncol 2002; 25: 632-633.
10. Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thurlimann B, Price KN, Castiglione-Gertsch M, Coates AS, Lindtner J, Collins J, Senn HJ, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M and Rudenstam CM. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 2000; 18: 3925-3935.
11. Evans AJ, James JJ, Cornford EJ, Chan SY, Burrell HC, Pinder SE, Gutteridge E, Robertson JF, Hornbuckle J and Cheung KL. Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol (R Coll Radiol) 2004; 16: 345-349.
12. Gaedcke J, Traub F, Milde S, Wilkens L, Stan A, Ostertag H, Christgen M, von Wasielewski R and Kreipe HH. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Mod Pathol 2007; 20: 864-870.
13. Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, Crowe JP, Choueiri TK, Dawson AE, Budd GT, Tubbs RR, Casey G and Weil RJ. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006; 30: 1097-1104.
14. Lorincz T, Toth J, Badalian G, Timar J and Szendroi M. HER-2/neu genotype of breast cancer may change in bone metastasis. Pathol Oncol Res 2006; 12: 149-152.
15. Nicolson GL. Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 1988; 7: 143-188.
16. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 571-572.
17. Hasebe T, Imoto S, Yokose T, Ishii G, Iwasaki M and Wada N. Histopathologic factors significantly associated with initial organ-specific metastasis by invasive ductal carcinoma of the breast: a prospective study. Hum Pathol 2008; 39: 681-693.
18. Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H and Tang P. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas. Hum Pathol 2008; 39: 1809-1815.
19. Elston CW and Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histo-pathology 1991; 19: 403-410.
20. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL and Wolff AC. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
21. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM and Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
22. Won KY, Kim GY, Kim YW, Song JY and Lim SJ. Clinicopathologic correlation of beclin-1 and bcl-2 expression in human breast cancer. Hum Pathol 2010; 41: 107-112.
23. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B and Senn HJ. Strategies for subtypes dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
24. Vlug EJ, van de Ven RA, Vermeulen JF, Bult P, van Diest PJ and Derksen PW. Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cell Oncol (Dordr) 2013; 36: 375-384.
25. Kim SK, Jung WH and Koo JS. Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer. Int J Clin Exp Pathol 2014; 7: 3224-3234.
26. Quan T, Xu Y, Qin Z, Robichaud P, Betcher S, Calderone K, He T, Johnson TM, Voorhees JJ and Fisher GJ. Elevated YAP and Its Down-stream Targets CCN1 and CCN2 in Basal Cell Carcinoma: Impact on Keratinocyte Prolife-ration and Stromal Cell Activation. Am J Pathol 2014; 184: 937-43.
27. Reddy P, Deguchi M, Cheng Y and Hsueh AJ. Actin cytoskeleton regulates Hippo signaling. PLoS One 2013; 8: e73763.
28. Desmouliere A, Guyot C and Gabbiani G. The stroma reaction myofibroblast: A key player in the control of tumor cell behavior. Int J Dev Biol 2004; 48: 509-517.
29. Park SY, Kim HM and Koo JS. Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer. Breast Cancer Res Treat 2015; 149: 727-741.
30. Jeong W, Kim SB, Sohn BH, Park YY, Park ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DS, Mills GB, Sood A and Lee JS. Activation of YAP1 Is Associated with Poor Prognosis and Response to Taxanes in Ovarian Cancer. Anti-cancer Res 2014; 34: 811-817.
31. Liu JY, Li YH, Lin HX, Liao YJ, Mai SJ, Liu ZW, Zhang ZL, Jiang LJ, Zhang JX, Kung HF, Zeng YX, Zhou FJ and Xie D. Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer 2013; 13: 349.
32. Wang L, Shi S, Guo Z, Zhang X, Han S, Yang A, Wen W and Zhu Q. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One 2013; 8: e65539.
33. Yeo MK, Kim SH, Kim JM, Huang SM, Kim MR, Song KS and Kim KH. Correlation of expression of phosphorylated and non-phosphorylated Yes-associated protein with clinicopathological parameters in esophageal squamous cell carcinoma in a Korean population. Anti-cancer Res 2012; 32: 3835-3840.
34. Song M, Cheong JH, Kim H and Noh SH. Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer. Anticancer Res 2012; 32: 3827-3834.
35. Wang Y, Dong Q, Zhang Q, Li Z, Wang E and Qiu X. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 2010; 101: 1279-1285.
36. Guo L and Teng L. YAP/TAZ for cancer therapy: opportunities and challenges (review). Int J Oncol 2015; 46: 1444-1452.